The Renova Therapeutics executive team includes experienced biopharmaceutical leaders with expertise in cardiovascular gene therapy, drug development, regulatory affairs, product registration and finance.

Roy Cosan

President and Interim CEO

Roy Cosan is a 32-year veteran of Johnson & Johnson (J&J), where he was Vice President of New Product Development and, in that role, launched a $billion+ product for schizophrenia, as well as a leading treatment for dementia. He was also a VP with the J&J Development Corporation, the venture capital arm of J&J, where he invested in 19 companies and was a director on 11 boards. Mr. Cosan is Member of the Cancer Prevention & Research Institute of Texas (CPRIT) Product Development Review Council and a product development reviewer, in which he plays a role in advising, guiding and determining funding for cancer research projects in Texas. He holds a B.B.A. with a concentration in marketing from Western Michigan University.

Catherine Bovenizer, CPA

Chief Financial Officer

Catherine Bovenizer, CPA, has 20 years of experience in financial management for a variety of public and closely held biotech and software companies. Most recently, Ms. Bovenizer was the Vice President of Finance and Chief Accounting Officer at Apricus Biosciences. In this role, she oversaw the team responsible for full-cycle accounting, audit management, accounting policy and procedure implementation, SEC reporting, human resources and IT/facilities, along with supporting investor relations. Prior to Apricus, she held roles of increasing responsibility at Ambit Biosciences, Senomyx, Ligand Pharmaceuticals and GeneFormatics. She began her career at Coopers & Lybrand. Ms. Bovenizer graduated magna cum laude from Claremont McKenna College with a B.A. in Economics, Accounting and Literature.

Waldemar Radziszewski, MD, Ph.D.

Chief Medical Officer

Before joining Renova Therapeutics, Dr. Radziszewski served as Vice President, Development Unit Immunology, and Site Head, Biopharmaceuticals Clinical Development, at Sandoz. He spent 18 years in various senior leadership positions within Merck Research Laboratories and later Janssen R&D, managing clinical operations and multiple early- and late-stage clinical development projects with small molecules and therapeutic proteins and peptides in diverse therapeutic areas. Dr. Radziszewski received both his M.D. and his Ph.D. from Nicolas Copernicus Academy of Medicine in Krakow, Poland, now known as Jagiellonian University Medical College. He completed a Fogarty Foundation Post-Doctoral Fellowship in pharmacology at the Department of Molecular and Clinical Pharmacology, UCLA School of Medicine. He then trained in Clinical and Anatomical Pathology at UCLA Medical Center in Los Angeles.

Peter Gengo, Ph.D.

VP, Preclinical Research and Pharmacology

An accomplished biochemical analytical pharmacologist with extensive knowledge of drug discovery and early drug development, Dr. Peter Gengo has more than 30 years of research and leadership experience, most recently in the Cardiovascular & Metabolic Disease unit at Merck & Co. Dr. Gengo also spent several years with Johnson & Johnson companies, including Janssen Pharmaceuticals as Scientific Director and Research Fellow. Dr. Gengo earned his Ph.D. at the University of Buffalo, graduating summa cum laude. He graduated magna cum laude from the State University of New York with a B.S. in Biology. He received a Medical Technology Degree & License (MT, ASCP) at the School of Medical Technology at Rochester General Hospital in Rochester, NY.